Peptide 101: GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper-carrying peptide that declines as we age and plays important roles in skin repair, collagen production, and hair growth. Topical products containing it are popular and have some reasonable clinical evidence for improving skin quality and wound healing. Injectable or systemic use has an interesting theoretical basis from gene expression studies but lacks the clinical trials needed to confirm safety and efficacy in humans.
How it works
GHK-Cu is like a master renovation coordinator for aging tissue. It simultaneously orders new building materials (collagen), stops the demolition crew (MMP inhibition), brings in new water pipes (angiogenesis), and sends renovation instructions to the blueprints (gene expression changes). It does this in the skin, scalp, wounds, and potentially throughout the body.
More specifically, GHK-Cu binds copper (Cu2+) in a tight complex and acts on multiple pathways: it activates TGF-beta signaling to stimulate collagen I and III, fibronectin, and decorin synthesis; it inhibits MMP activity, reducing collagen degradation; it promotes VEGF-driven angiogenesis; it modulates gene expression of over 4,000 human genes (including upregulating DNA repair and anti-aging genes while downregulating inflammatory and oncogenic pathways per Pickart's genomic analyses); and it activates Wnt/beta-catenin signaling in hair follicles, extending anagen phase.
What the evidence shows
Overall strength of the evidence, by our read: Emerging. Some of what that rests on:
GHK-Cu stimulates collagen synthesis and improves skin parameters: double-blind trial (2008) — A double-blind, placebo-controlled study showed topical GHK-Cu significantly improved skin density, skin thickness, and collagen content compared to placebo and vitamin C after 12 weeks of twice-daily application.
GHK-Cu in wound healing: clinical evaluation in dermal wounds (2017) — GHK-Cu topical application significantly accelerated wound re-epithelialization, reduced wound area, and improved final scar appearance compared to standard wound care in a clinical study.
GHK-Cu modulates gene expression in human dermal fibroblasts (2018) — Microarray analysis revealed GHK-Cu modulated over 4,000 genes in human fibroblasts, upregulating collagen synthesis, DNA repair, and inflammation-modulating pathways while downregulating genes associated with senescence and cancer.
Note, preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety
Topical GHK-Cu is generally very well-tolerated. Mild skin irritation possible at high concentrations. Green-blue discoloration of skin at application site with very high doses (copper pigment). Systemic injectable GHK-Cu: safety data are very limited. Theoretical risk of copper toxicity with excessive systemic administration.
Reasons to avoid it, or to talk to a clinician first:
Known hypersensitivity to GHK-Cu, copper peptides, or any component
Wilson's disease or copper metabolism disorders
Pregnancy or breastfeeding
Children under 18
Active skin cancer at application site (may promote tissue remodeling)
This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.
Questions worth bringing to a clinician
For my degree of skin aging or hair thinning, is topical GHK-Cu sufficient or would injectable/systemic GHK-Cu provide additional benefit?
Are there any concerns about systemic copper accumulation with long-term use, particularly if I take copper-containing supplements?
How does GHK-Cu compare to retinoids, peptide growth factors, or platelet-rich plasma for my specific skin concern?
New research, translated
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
2026-09-30 · INTERVENTIONAL · mazdutide
A Chinese trial testing whether mazdutide (a weekly injectable in the same family as Ozempic and Mounjaro) can actually push type 2 diabetes into remission — meaning normal blood sugar without needing diabetes medication — rather than just controlling it. They're enrolling people whose sugar is still too high on diet and exercise alone, or on a single drug like metformin. Neither the patients nor the doctors know who gets the real drug versus placebo.
Tirzepatide for Treatment of CCCA
2026-09-15 · INTERVENTIONAL · tirzepatide
A small first-look trial asking whether tirzepatide (Mounjaro/Zepbound) can help a type of permanent, scarring hair loss called central centrifugal cicatricial alopecia, which destroys the follicle for good once scarring finishes. The thinking is that the drug's effects on inflammation and metabolism might calm things down while the follicles are still salvageable. This is a pilot — the goal is to see whether the idea is worth a bigger study at all.
QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)
2026-09-01 · INTERVENTIONAL · mazdutide
Tests whether stacking kidney-protective drugs works better than fewer of them in people with early kidney damage from type 2 diabetes. Everyone stays on a standard blood-pressure drug as the baseline, then gets sorted at random into four different combinations adding empagliflozin, finerenone, and mazdutide. The question is simply how many of these it's worth piling on to slow kidney decline.
What readers are asking
Topics we'll be tracking:
Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
Pavlovian conditioned approach with different reward magnitudes reveals opposing effects of acute and chronic semaglutide treatment
Semaglutide engages distinct brainstem-to-hypothalamus circuits to suppress motivated feeding and regulate ketogenesis and energy expenditure
About GHK-Cu:
GHK-Cu has NOT been approved by the U.S. Food and Drug Administration for any medical use. As of 2023-09-29, the FDA placed this substance on the Category 2 list of bulk drug substances under Section 503A of the FD&C Act, meaning compounding pharmacies are prohibited from compounding it under the FDA's interim policy. Research discussed below may include preclinical, animal, or preliminary studies that do not establish safety or efficacy in humans. Compounded versions of GHK-Cu are NOT the same as FDA-approved products. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality. The FDA has warned that compounded versions may contain different salt forms, concentrations, or impurities. Discuss the risks and regulatory status of compounded medications with your prescriber. IMPORTANT: The available research on GHK-Cu consists primarily of preclinical studies (animal models and/or in vitro experiments). These results may not translate to humans. No controlled human clinical trials have established the safety or efficacy of this substance for any indication. NOTE: A policy announcement regarding potential reclassification of this substance was made in February 2026. However, as of the date of this content, no formal FDA rule change has been published in the Federal Register. The current regulatory status described above remains in effect until a formal rule is finalized.
Medical disclaimer:
This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.